Skip to content

management of UTI in pregnancy with Unani formulation and its comparison with tablet Nitrofurantoin

Management of Tadiya majariye boul fi ayyam-e-hamal (Gestational urinary tract infection) with Citrullus vulgaris Schrad-Tukhm-e-Tarbuz and its comparison with Nitrofurantoin - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/068419
Enrollment
40
Registered
2024-06-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N00-N99- Diseases of the genitourinary system

Interventions

Intervention1: Group A(Test group):- Drug: TUKHM-E-TARBUZ Citrullu vulgaris Schrad: Oral administration of Sheera-e-Tukhm-e-Tarbuz Citrullus vulgaris Schrad 3gram twice a day for 10 days Control Inter
Nitrofurantoin 100mg: Oral administration of Tablet Nitrfurantoin 100mg once a day for 10 days Control Intervention2: Group B( Control group):- Drug: Tablet Nitrofurantoin 100mg: Oral administration o

Sponsors

PG department of Obstetrics and Gynaecology Iluml Qabalat wa Amaraze Niswan
Lead Sponsor
Government Nizamia Tibbi College and general hospital charminar
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1.Primigravidae and multiparous. 2.Pregnant women with Gestational age up to 24 weeks. 3.Age between 18 to 40 years. 4.Complaining of burning micturition, polyuria, dysuria, lower abdominal pain, Tightness of abdomen, nausea and vomiting, lower backache, nocturia, frequency and urgency and suprapubic pain. 5.Already diagnosed cases.

Exclusion criteria

Exclusion criteria: 1.High risk pregnancies such as pre eclampsia, gestational diabetes mellitus and oligohydramnios. 2.Patient with systemic disease. 3.Vaginal infections. 4.HIV, HbsAg, VDRL positive patients. 5.Immuno compromised patients.

Design outcomes

Primary

MeasureTime frame
Absence of pus cells in urinalysis and alleviation of symptoms.Timepoint: complete urine examination after the treatment of 10 days.

Secondary

MeasureTime frame
prevention & complication of gestational urinary tract infection & perinatal outcome.Timepoint: at 1 week after delivery & 4 weeks after delivery

Countries

India

Contacts

Public ContactDr Maseeha Naaz

PG department of Obstetrics and Gynaecology (Ilmul Qabalat wa Amaraze Niswan)

drssntc@gmail.com9908624090

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026